Biotech Values

[DewDiligence]

Index to Recent Posts on Abbott

Xience and vascular business:
#msg-32873087 Xience ramp exceeds forecasts:
#msg-32217694 Ditto
#msg-29264356 Xience blows away Taxus at two years
#msg-30452522 FDA approves Xience
#msg-32869939 ABT progresses on dissolving stent


Humira and drug business:
#msg-32873850 Humira has become a mega-blockbuster
#msg-26156472 FDA approves Humira for plaque psoriasis
#msg-26869744 FDA approves Simcor
#msg-11890439 Crestor+TriCor combo pill
#msg-29106939 ABT showcases ADHD portfolio


Corporate and miscellaneous:
#msg-32844386 New $5B buyback authorization
#msg-31637906 ABT cuts 1,000 jobs
#msg-32652322 Overview from investopedia
#msg-29708517 Musings on TriCor patent case
#msg-31102936 Musings on Norvir lawsuit
#msg-30397021 ABT invests in Ibis Biosciences


<font size=3><font color=red> “The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”